Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Levodopa with ODM-104 Pellet Formulations
NCT03140956Phase 1Completed
- Sponsor
- Orion Corporation
- Start
- Apr 2017
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of neluxicapone in Parkinson's disease (PD) (8 arms), sponsored by Orion Corporation. Primary endpoint: Pharmacokinetics (Cmax) of levodopa at 24 hours. Started Apr 2017; status: completed.
02
Drugs
neluxicapone
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT03140956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03140956.